Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study

Abstract Objectives To investigate the safety and effectiveness of mepolizumab (MPZ), an anti-interleukin-5 antibody, as remission induction therapy for severe eosinophilic granulomatosis with polyangiitis (EGPA). Methods The clinical courses of patients with severe EGPA over 6 months were retrospec...

Full description

Bibliographic Details
Main Authors: Masanobu Ueno, Ippei Miyagawa, Takafumi Aritomi, Koichi Kimura, Shigeru Iwata, Kentaro Hanami, Syunsuke Fukuyo, Satoshi Kubo, Yusuke Miyazaki, Shingo Nakayamada, Yoshiya Tanaka
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Arthritis Research & Therapy
Subjects:
Eosinophilic granulomatosis with polyangiitis
Corticosteroid
Mepolizumab
Induction therapy
Online Access:https://doi.org/10.1186/s13075-022-02845-3

Internet

https://doi.org/10.1186/s13075-022-02845-3

Similar Items